These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 11360024

  • 1. Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics.
    Iida Y, Nishi S, Asada A.
    Ther Drug Monit; 2001 Jun; 23(3):192-7. PubMed ID: 11360024
    [Abstract] [Full Text] [Related]

  • 2. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
    Watanabe M, Iwahashi K, Kugoh T, Suwaki H.
    Clin Neuropharmacol; 1998 Jun; 21(2):122-6. PubMed ID: 9579299
    [Abstract] [Full Text] [Related]

  • 3. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K, Ieiri I, Shimamoto J, Yukawa E, Imai J, Ninomiya H, Yamada H, Otsubo K, Higuchi S, Tashiro N.
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [Abstract] [Full Text] [Related]

  • 4. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ.
    Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
    [Abstract] [Full Text] [Related]

  • 5. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ, Yen MF, Hu OY, Lin MS, Hsiong CH, Hung CC, Liou HH.
    Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
    [Abstract] [Full Text] [Related]

  • 6. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K.
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [Abstract] [Full Text] [Related]

  • 7. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
    Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M.
    Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
    [Abstract] [Full Text] [Related]

  • 8. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.
    Yukawa E, Mamiya K.
    J Clin Pharm Ther; 2006 Jun; 31(3):275-82. PubMed ID: 16789993
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
    Argikar UA, Cloyd JC, Birnbaum AK, Leppik IE, Conway J, Kshirsagar S, Oetting WS, Klein EC, Remmel RP.
    Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.